败血性休克中心室-动脉 (解) 合:当前和即将到来的血液动力学药物的影响
Zoé Demailly1,2, Emmanuel Besnier2, Fabienne Tamion1
1Medical Intensive Care Unit, UNIROUEN, INSERM U1096, CHU Rouen, Normandie Université, Rouen, France.
Frontiers in cardiovascular medicine
|June 16, 2023
概括
败血症会导致复杂的血液动力学变化,影响心脏功能. 了解心室 - 动脉合 (VAC) 和其测量对于改善败血症休克治疗和降低高死亡率至关重要.
科学领域:
- 关键护理医学 关键护理医学
- 心血管生理学心血管生理学
- 血液动力学 血液动力学
背景情况:
- 败血症是一种危及生命的疾病,其特点是分布性休克.
- 前负荷,后负荷和心脏收缩率的变化是败血症休克的标志.
- 尽管血液动力学监测和药物方面的进展,但败血性休克死亡率仍然很高.
研究的目的:
- 审查目前对心室动脉合 (VAC) 的理解和测量工具.
- 讨论在败血性休克中腹腔动脉脱的证据.
- 分析血液动力学药物对性休克中VAC的影响.
主要方法:
- 文献综述侧重于腹腔动脉合 (VAC) 在败血症.
- 对侵入性和非侵入性血液动力学监测技术的分析.
- 临床研究和药理干预措施的评估.
主要成果:
- 腹腔动脉合 (VAC) 整合了关键的血液动力学参数 (前负荷,后负荷,收缩性).
- 证据支持腹腔动脉脱是感染性休克病理生理学的重要因素.
- 当前的血液动力学监测工具在实时VAC评估方面存在局限性.
结论:
- 优化心室动脉合 (VAC) 可能是败血症休克的治疗目标.
- 需要进一步的研究来完善VAC测量及其临床应用.
- 了解VAC的作用可以指导开发更有效的血动力学策略,以治疗败血性休克.
关键词:
这就是阿佩林 (apelin) 的意思.杜布他胺是一种多巴胺胺.血液动力学药物 血液动力学药物在左边的房间里.北上腺素 (NE) 北上腺素 (NE)这是一种血症.腹腔 - 动脉合器这是β-阻断剂.更多相关视频
相关概念视频
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
469
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
469
Heart Failure Drugs: Inotropic Agents
641
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
641
Heart Failure Drugs: β-Blockers
382
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
382
Blood Pressure Imbalances and Circulatory Shock
819
Disorders affecting blood volume, vascular tone, or vascular function can disrupt vascular homeostasis, including conditions like hypertension, hemorrhage, and shock.
Blood Pressure: Hypertension and Hypotension
Normal blood pressure is 120/80 mm Hg. Elevated blood pressure is 120-129/under 80 mm Hg. Hypertension, warranting treatment at 130/80 mm Hg, is often asymptomatic and can lead to severe cardiovascular events, aneurysms, peripheral arterial disease, chronic renal disease, or cardiac...
Blood Pressure: Hypertension and Hypotension
Normal blood pressure is 120/80 mm Hg. Elevated blood pressure is 120-129/under 80 mm Hg. Hypertension, warranting treatment at 130/80 mm Hg, is often asymptomatic and can lead to severe cardiovascular events, aneurysms, peripheral arterial disease, chronic renal disease, or cardiac...
819
Heart Failure II: Pathophysiology
16
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
16
Heart Failure V: Medical Management
16
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
16


